Dr. Bill Hanlon has been an active contributor to the development of innovative new medicines for more than 35 years, holding positions of increasing scientific, leadership and business responsibility. Trained as a biochemist/cell biologist, Dr. Hanlon spent the first part of his career in drug discovery identifying novel small molecules effective in targeting molecular mechanisms regulating inflammatory and immunological disease processes. For the last 20 years, Dr. Hanlon has focused his attention in early and late clinical development as a regulatory affairs expert and business leader. Currently, Dr. Hanlon is Senior Vice President, Head of Real-World Data Product Strategy at Labcorp in Princeton, NJ where he is responsible for developing real-world data related products, applications and analytical tools that can be used to generate insights related to patient disease and clinical trial-enabling services.

In addition to his role at ILSE, Bill also represented the American Clinical Laboratory Association on the inaugural Governing Committee of the National Evaluation System for health Technology Coordinating Center (NESTcc) (2017-2021). Bill also served as a Board observer for MC-10, Inc. (2017-2020), a medical digital device company, invested in by LabCorp and currently is a Board Observer at BioSpectal, a European medical software as a device company, Prognos Health, a Real-World health data marketplace, and Circuit Clinical, an Integrated Research Organization, all invested in by Labcorp.

Dr. Hanlon received his PhD in biochemistry and cell biology jointly conferred from the University of Medicine and Dentistry of New Jersey (UMDNJ) and Rutgers Graduate School in Piscataway, NJ. He completed his post doctoral training at Merck Research Laboratories in Rahway, NJ. He is the author of 21 scientific publications, a book chapter on protein profiling and inventor of 2 patents.